Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.450 +0.050 (+3.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
Why Did Allarity Therapeutics Stock Double In Value Today?
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Top stock movements in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Tuesday's session: top gainers and losers
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Crude Oil Down 2%; US Durable Goods Orders Decline In July
 
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
US Stocks Mixed; American Woodmark Posts Downbeat Sales
 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Stock Market Today: S&P 500, Nasdaq Futures Decline— Palo Alto, XP, Allarity Earnings In Focus
U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
From Allarity Therapeutics, Inc.
Via GlobeNewswire
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.